|Systematic (IUPAC) name|
|ATC code||R03 (+fluticasone)
|Molecular mass||486.43 g/mol|
Vilanterol (USAN) is a long-acting beta-2 agonist drug, which in May 2013 was approved in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Vilanterol is not available on its own, but only in combination with fluticasone Furoate (Breo in the US; Relvar Ellipta in the UK).
- "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Retrieved 10 May 2013.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|